JPMorgan Chase & Co. Has Lowered Expectations for Ardent Health (NYSE:ARDT) Stock Price

Ardent Health (NYSE:ARDT) had its price objective decreased by research analysts at JPMorgan Chase & Co. from $12.00 to $11.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 29.37% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on ARDT. Bank of America decreased their target price on Ardent Health from $12.00 to $10.00 and set an “underperform” rating on the stock in a research report on Thursday, November 13th. Guggenheim lowered their price objective on Ardent Health from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Mizuho cut their target price on Ardent Health from $20.00 to $12.00 and set an “outperform” rating for the company in a research note on Thursday, December 18th. The Goldman Sachs Group started coverage on shares of Ardent Health in a research note on Tuesday, October 14th. They set a “neutral” rating and a $19.00 price target on the stock. Finally, Stephens dropped their price objective on shares of Ardent Health from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Friday, November 14th. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $14.58.

Ardent Health Stock Performance

Shares of ARDT stock opened at $8.50 on Tuesday. Ardent Health has a fifty-two week low of $8.22 and a fifty-two week high of $15.65. The stock’s 50-day moving average is $8.85 and its two-hundred day moving average is $11.63. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.08 and a quick ratio of 1.95. The firm has a market cap of $1.22 billion, a P/E ratio of 5.86, a PEG ratio of 4.81 and a beta of 0.72.

Ardent Health (NYSE:ARDT) last released its quarterly earnings results on Wednesday, November 12th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.10. Ardent Health had a net margin of 3.24% and a return on equity of 19.02%. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.55 billion. Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. Analysts predict that Ardent Health will post 1.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ardent Health

Several hedge funds and other institutional investors have recently made changes to their positions in ARDT. Voleon Capital Management LP acquired a new stake in shares of Ardent Health during the third quarter worth $571,000. Verition Fund Management LLC boosted its holdings in Ardent Health by 540.6% during the third quarter. Verition Fund Management LLC now owns 85,561 shares of the company’s stock worth $1,134,000 after buying an additional 72,205 shares during the last quarter. Prelude Capital Management LLC grew its position in shares of Ardent Health by 30.3% during the 3rd quarter. Prelude Capital Management LLC now owns 18,303 shares of the company’s stock worth $243,000 after buying an additional 4,259 shares during the period. Millennium Management LLC increased its stake in shares of Ardent Health by 6.6% in the 3rd quarter. Millennium Management LLC now owns 1,269,605 shares of the company’s stock valued at $16,822,000 after acquiring an additional 78,861 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of Ardent Health by 2.5% in the 3rd quarter. Bank of America Corp DE now owns 310,563 shares of the company’s stock valued at $4,115,000 after acquiring an additional 7,610 shares during the period.

More Ardent Health News

Here are the key news stories impacting Ardent Health this week:

• Positive Sentiment: Contrarian/bull case published outlining reasons to buy ARDT amid the selloff; may attract value investors looking past near‑term litigation risk. A Bull Case Theory
• Negative Sentiment: Multiple national plaintiff law firms have filed or issued investor alerts about a securities class action alleging accounting/revenue recognition and reserve misstatements tied to Ardent’s Q3 2025 results; firms are soliciting lead‑plaintiff applicants with a March 9, 2026 deadline — this increases the risk of litigation expense, management distraction, and prolonged share‑price pressure. Hagens Berman notice
• Negative Sentiment: Numerous additional firms (Kirby McInerney, Rosen, Bragar Eagel & Squire, Glancy Prongay & Murray, Schall, Kahn Swick & Foti, Pomerantz, Wolf Haldenstein, Levi & Korsinsky, BFA Law, etc.) have issued investor reminders or filed claims — amplifying media coverage and potential claimant interest, which can prolong uncertainty and downside risk for ARDT. Example notice: GlobeNewswire reminder
• Negative Sentiment: JPMorgan lowered its price target on ARDT from $12 to $11 and maintains a neutral rating — the cut signals reduced near‑term analyst confidence and may limit buying from institutional investors that follow bank research. Benzinga analyst note

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.